

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of	)	
	)	
Ronald ROOKE	)	Group Art Unit: Unassigned
	)	
Application No.: New	)	Examiner: Unassigned
	)	
Filed: Herewith	)	Confirmation No.: Unassigned
	)	
For: ANTI-INFLAMMATORY VECTORS	)	
	)	
	)	
	)	

**FIRST**  
**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicant hereby submits the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98.

This statement is being submitted within three (3) months of the filing of this application or before the first Office Action on the merits, within the time period set forth in 37 C.F.R. § 1.97(b).


Copies of the listed documents were previously submitted or cited in prior Application Serial No. 09/969,770, filed October 4, 2001, upon which Applicant relies for the benefits provided in 35 U.S.C. § 120. In accordance with 37 C.F.R. § 1.98(d), copies of the listed documents are not enclosed.

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner-initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date: September 26, 2003

By:   
Jennifer A. Topmiller, Ph.D.  
Registration No. 50,435

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	ATTORNEY'S DKT NO. 032751-094	APPLICATION NO. New
	APPLICANT Ronald ROOKE	
	FILING DATE September 26, 2003	GROUP UNASSIGNED

## U.S. PATENT DOCUMENTS

Examiner Initials	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication (MM-DD-YYYY)
	Number	Kind Code (if known)		

## FOREIGN PATENT DOCUMENTS

[illegible]

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	TOLLEFSON et al., "The Adenovirus Death Protein (E3-11.6K) is Required at Very Late Stages of Infection for Efficient Cell Lysis and Release of Adenovirus from Infected Cells", J. Virol., 1996, Vol. 70, p. 2296-2306, American Soc for Microb
	SIGNAS et al., "An Adenovirus Glycoprotein Binds Heavy Chains of Class I Transplantation Antigen from Man and Mouse", Nature, Vol. 1982, 299, p. 175-178, Macmillian Journals Ltd.
	BURGERT et al., "An Adenovirus Type 2 Glycoprotein Blocks Cell Surface Expression of Human Histocompatibility Class I Antigens", Cell, 1985 Vol. 41, p. 987-997, MIT
	ANDERSSON et al., "Reduced Allorecognition of Adenovirus-2 Infected Cells", J. Immunol., 1987, Vol. 138, p. 3906-3966, The American Association of Immunologists
	BROWNING AND RIBOLINI, "Studies of the Differing Effects of Tumor Necrosis Factor and Lymphotoxin on the Growth of Several Human Tumor Lines", J. Immunol., 1989, Vol. 143, p. 1859-1967, The American Association of Immunologists
	MESTAN et al., "Antiviral Effects of Recombinant Tumour Necrosis Factor <i>In Vitro</i> ", Nature, 1986, Vol. 323, p. 816-819
	YANG et al., "Cellular Immunity to Viral Antigens Limits E1-deleted Adenoviruses for Gene Therapy", Proc. Natl. Acad. Sci. USA, 1994, Vol. 91, p. 4407-4411, Medical Sciences
	ZSENGELLER et al., Human Gene Therapy, 1995, Vol. 6, p. 457-467, Mary Ann Liebert, Inc. Publishers
	YANG et al, "Cellular and Humoral Immune Responses to Viral Antigens Create Barriers to Lung-Directed Gene Therapy with Recombinant Adenoviruses", J. Virology, 1995, Vol. 69, p. 2004-2015, American Society for Microbiology
	LLAN et al., "Insertion of the Adenoviral E3 Region into a Recombinant Viral Vector Prevents Antiviral Humoral and Cellular Immune Responses and Permits Long-Term Gene Expression", Proc. Natl. Acad. Sci. USA, 1997, Vol. 94, p. 2587-2592, Medical Sciences
	WOLD et al., "E3 Transcription Unit of Adenovirus", Current Topics in Microbiology and Immunology, 1995, Vol. 199, p.237-274, St. Louis University School of Medicine, Dept. of Molecular and Immunology
Examiner Signature	Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Substitute for form 1449A/PTO	ATTORNEY'S DKT No. 032751-094	APPLICATION No. New
	APPLICANT Ronald ROOKE	
	FILING DATE September 26, 2003	GROUP UNASSIGNED
	<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	

U.S. PATENT DOCUMENTS				
Examiner Initials	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication (MM-DD-YYYY)
	Number	Kind Code (if known)		
	6,100,086		Kaplan et al.	08-08-2000
	5,851,806		Kovesdi et al.	12-22-1998

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Foreign Patent Document		Country	Date of Publication (MM-DD-YYYY)	Translation	
	Number	Kind Code (if known)			Yes	no
	WO 99/02658	A1	PCT	01-21-1999	X	
	EP 0974668	A1	European Patent Office	01-26-2000	X	
	WO 96/12030	A1	PCT	04-25-1996		X
	EP 0707071	A1	European Patent Office	04-17-1996	X	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	HARROD, K.S. et al., "Adenoviral E3-14.7K Protein in LPS-induced Lung Inflammation", American Journal of Physiology, April 2000, Volume 278, No. 4, Part 1, pp. L631-L639.		
	KRAJCSI, P. et al., "The Adenovirus E3-14.7K Protein and the E3-10.4K/14.5K Complex of Proteins, Which Independently Inhibit Tumor Necrosis Factor (TNF)-induced Apoptosis, Also Independently Inhibit TNF-induced Release of Arachidonic Acid.", Journal of Virology, 1996, Volume 70, No. 8, pp. 4904-4913.		
	GANTZER, M. et al., "Constitutive Expression of the Adenovirus E3-14.7K Protein Does Not Prolong Adenovirus Vector DNA Persistence but Protects Mice Against Lipopolysaccharide-Induced Acute Hepatitis.", Human Gene Therapy, May 2002, Volume 13, No. 8, pp. 921-933.		
	International Search Report, June 7, 2002, for EPO Application No. 01120916.		
Examiner Signature		Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.